Latin American societies show lower levels of political trust when compared to other regions of the world. The lack of trust in institutions can led to ineffective management of public affairs, social crises, lack of transparency, economic problems and even difficulties in countering pandemics. The objective of this work is to build an index (LADI) that provides a measure of the level of perceived distrust in the institutions of the different Latin American countries and its variations over the period from 2008 to 2018. The data used for this analysis are of a subjective nature and come from the series of surveys provided by Latinobarómetro. To develop the analysis, we have used a quantitative approach of a partially non-compensatory aggregative type, known as Adjusted Mazziotta and Pareto Index. The results show a generalized increase of distrust in the years 2017 and 2018 for several Latin American countries. On the other hand, in countries where the rule of law is more consolidated, a best perception of the functioning of democracy emerges.
1 year. Secondary outcomes were determined by Kaplan-Meier analyses.Results: This study included 107 FEVAR patients that were predominantly treated for juxtarenal aneurysm repair (90.7%) and 40 BEVAR patients that were mostly treated for repair of thoracoabdominal aneurysms (90.0%). From these, 90 FEVAR and 26 BEVAR patients were included for imaging analysis ($2 postoperative computed tomography angiographies [CTAs]). Following FEVAR, aneurysm sac volumes decreased significantly up to 24 months and remained constant thereafter, whereas aneurysm sac volumes after BEVAR did not change significantly over time (Fig 1). At last imaging follow-up, 68.9% of FEVAR treated aneurysms showed >5% shrinkage vs 29.8% after BEVAR (P < .001). FEVAR patients had higher freedom from aneurysm-related complications (3-year: FEVAR: 0.65.7%; 95% CI, 55.7%-77.6% vs BEVAR: 51.4%; 95% CI, 32.5%-81.4%; log-rank P ¼ .035) and showed higher freedom from secondary interventions (FEVAR: 84.6%; 95% CI, 77.1%-93.0% vs BEVAR: 74.8%; 95% CI, 60.9%-91.9%; log-rank P ¼ .034). However, among groups, there was no difference in freedom from endoleaks type I/III (3-year: FEVAR, 89.9%; 95% CI, 83.7%-96.6% vs BEVAR, 80.0%; 95% CI, 64.5%-99.4%; log-rank P ¼ .13). Finally, early aneurysm sac shrinkage showed significant higher freedom from the composite outcome (log-rank P ¼ .022) (Fig 2).Conclusions: Initial sac regression at 1 year is significantly associated with improved clinical outcomes; freedom from aneurysm-related complications. Both BEVAR and FEVAR need secondary interventions in the first year to maintain clinical success. The proportion of patients with sac regression after BEVAR is lower compared with FEVAR, and therefore will probably require more intensified surveillance.
To describe a case of endovascular bailout strategy during stent-graft thrombotic complication in an endovascular procedure for complex TASC II D aortoiliac lesion. A 77-year-old patient was admitted at our institution with bilateral lower limb rest pain due to aortoiliac obstructive disease in a previous aortobifemoral bypass grafting with an asymptomatic Sars-CoV-2 infection. We planned an anatomic reconstruction of the aortoiliac segment with an unimodular bifurcated stent-graft. During the procedure, we observed a preocclusive thrombosis of the aortic portion requiring endovascular thrombectomy with vacuum assisted system followed by a successfully kissing-stent endolining. The post-operative period was uneventful and patient was discharged on the 14th post-operative day. Endovascular thrombectomy may be a helpful strategy during thrombotic complication of complex reconstructions of obstructive aortoiliac disease avoiding surgical conversion to laparotomy.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.